/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...
The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE American: GRF) today declared a year-end distribution of $0.37 per share in cash. The record date for this distribution is November 18, 2022, and the...
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is...
The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...
The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...
The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.97 per share in cash. The record date for this distribution is November 19, 2021, and...
/PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track...
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint...
The Board of Directors of Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) at a regular Board meeting today unanimously elected Anne M. Nichols, CFA as a Director.
First-in-human study evaluating recombinant hyperimmunes